

Appendix S1

This appendix contains references for all articles found in GREAT database for our systematic review.

**Full text articles: E1-250;E251-287**

**Abstracts:E288-359**

**Excluded articles: protocol only (E360-368), no English or German abstract or full text available (E369-373), paper reported on a study already included (E374-377), paper was conference publication and not available as abstract or full text (E378)**

- E1. Abramovits W, Boguniewicz M, Adult Atopiclair Study G. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. *J Drugs Dermatol* 2006; 5: 236-244.
- E2. Abramovits W, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. *Skinmed* 2010; 8: 72-79.
- E3. Amestejani M, Salehi BS, Vasigh M, Sobhkhiz A, Karami M, Alinia H, et al. Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study. *J Drugs Dermatol* 2012; 11: 327-330.
- E4. Amichai B, Grunwald MH. A randomized, double-blind, placebo-controlled study to evaluate the efficacy in AD of liquid soap containing 12% ammonium lactate + 20% urea. *Clin Exp Dermatol* 2009; 34: e602-604.
- E5. Anderson C, Lis-Balchin M, Kirk-Smith M. Evaluation of massage with essential oils on childhood atopic eczema. *Phytother Res* 2000; 14: 452-456.
- E6. Antiga E, Volpi W, Torchia D, Fabbri P, Caproni M. Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis. *Clin Exp Dermatol* 2011; 36: 235-241.
- E7. Araujo CP, Gomes J, Vieira AP, Ventura F, Fernandes JC, Brito C. A proposal for the use of new silver-seaweed-cotton fibers in the treatment of atopic dermatitis. *Cutan Ocul Toxicol* 2013; 32: 268-274.
- E8. Arenberger P, Drozenová H, Hladicova M, Holcova S. Additive Wirkung von Heparin und Levomenol bei Neurodermitis. *Aktuelle Derm* 2010; 36: 217-221.
- E9. Arkwright PD, David TJ. Intradermal administration of a killed *Mycobacterium vaccae* suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. *J Allergy Clin Immunol* 2001; 107: 531-534.
- E10. Arkwright PD, David TJ. Effect of *Mycobacterium vaccae* on atopic dermatitis in children of different ages. *Br J Dermatol* 2003; 149: 1029-1034.
- E11. Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol* 2011; 64: 502-507.
- E12. Aschoff R, Schwanebeck U, Brautigam M, Meurer M. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. *Exp Dermatol* 2009; 18: 24-29.
- E13. Back, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2001; 15: 34-38.
- E14. Bae BG, Oh SH, Park CO, Noh S, Noh JY, Kim KR, et al. Progressive muscle relaxation therapy for atopic dermatitis: objective assessment of efficacy. *Acta Derm Venereol* 2012; 92: 57-61.
- E15. Bangert C, Strober BE, Cork M, Ortonne JP, Luger T, Bieber T, et al. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. *Dermatology* 2011; 222: 36-48.
- E16. Beattie PE, Lewis-Jones MS. A pilot study on the use of wet wraps in infants with moderate atopic eczema. *Clin Exp Dermatol* 2004; 29: 348-353.
- E17. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. *Eur J Dermatol* 2005; 15: 31-36.
- E18. Bemanian MH, Movahedi M, Farhoudi A, Gharagozlou M, Seraj MH, Pourpak Z, et al. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. *Iran J Allergy Asthma Immunol* 2005; 4: 139-143.
- E19. Berardesca E, Barbareschi M, Veraldi S, Pimpinelli N. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. *Contact Dermatitis* 2001; 45: 280-285.
- E20. Berth-Jones J, Arkwright PD, Marasovic D, Savani N, Aldridge CR, Leech SN, et al. Killed *Mycobacterium vaccae* suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *Clin Exp Allergy* 2006; 36: 1115-1121.
- E21. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hoogheem O, Allegra F, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *BMJ* 2003; 326: 1367.
- E22. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. *Br J Dermatol* 2002; 147: 324-330.
- E23. Bieber T, Vick K, Folster-Holst R, Belloni-Fortina A, Stadler G, Worm M, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. *Allergy* 2007; 62: 184-189.
- E24. Bigliardi PL, Stammer H, Jost G, Ruffli T, Buchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. *J Am Acad Dermatol* 2007; 56: 979-988.
- E25. Bissonnette R, Chen G, Bolduc C, Maari C, Lyle M, Tang L, et al. Efficacy and safety of topical WBI-1001 in the treatment of

- atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. *Arch Dermatol* 2010; 146: 446-449.
- E26. Bissonnette R, Maari C, Provost N, Bolduc C, Nigen S, Rougier A, et al. A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. *J Cosmet Dermatol* 2010; 9: 16-21.
- E27. Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. *Br J Dermatol* 2012; 166: 853-860.
- E28. Boguniewicz M, Zeichner JA, Eichenfield LF, Hebert AA, Jarratt M, Lucky AW, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. *J Pediatr* 2008; 152: 854-859.
- E29. Breneman D, Fleischer AB, Jr., Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. *J Am Acad Dermatol* 2008; 58: 990-999.
- E30. Breneman D, Fleischer AB, Jr., Kaplan D, Lebwohl M, Miller B, Pariser D, et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. *J Drugs Dermatol* 2005; 4: 330-336.
- E31. Breneman DL, Hanifin JM, Berge CA, Keswick BH, Neumann PB. The effect of antibacterial soap with 1.5% triclocarban on *Staphylococcus aureus* in patients with atopic dermatitis. *Cutis* 2000; 66: 296-300.
- E32. Brenninkmeijer EE, Spuls PI, Lindeboom R, van der Wal AC, Bos JD, Wolkerstorfer A. Excimer laser vs. clobetasol propionate 0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. *Br J Dermatol* 2010; 163: 823-831.
- E33. Brothers S, Asher MI, Jaksic M, Stewart AW. Effect of a *Mycobacterium vaccae* derivative on paediatric atopic dermatitis: a randomized, controlled trial. *Clin Exp Dermatol* 2009; 34: 770-775.
- E34. Brouwer ML, Wolt-Plompen SA, Dubois AE, van der Heide S, Jansen DF, Hoijer MA, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. *Clin Exp Allergy* 2006; 36: 899-906.
- E35. Byremo G, Rod G, Carlsen KH. Effect of climatic change in children with atopic eczema. *Allergy* 2006; 61: 1403-1410.
- E36. Byun HJ, Lee HI, Kim B, Kim MN, Hong H, Choi Y, et al. Full-spectrum light phototherapy for atopic dermatitis. *Int J Dermatol* 2011; 50: 94-101.
- E37. Callaway J, Schwab U, Harvima I, Halonen P, Mykkanen O, Hyvonen P, et al. Efficacy of dietary hempseed oil in patients with atopic dermatitis. *J Dermatolog Treat* 2005; 16: 87-94.
- E38. Canpolat F, Erkocoglu M, Tezer H, Kocabas CN, Kandi B. Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. *Eur Rev Med Pharmacol Sci* 2012; 16: 1989-1993.
- E39. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. *Eur J Dermatol* 2001; 11: 209-213.
- E40. Caproni M, Torchia D, Antiga E, Terranova M, Volpi W, del Bianco E, et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. *Br J Dermatol* 2007; 156: 312-319.
- E41. Cato A, Swinehart JM, Griffin EI, Sutton L, Kaplan AS. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. *Int J Dermatol* 2001; 40: 232-236.
- E42. Chapman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Shull T, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. *J Am Acad Dermatol* 2005; 53: S177-185.
- E43. Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *Int Arch Allergy Immunol* 2011; 155: 141-148.
- E44. Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. *Br J Dermatol* 2002; 146: 432-439.
- E45. Cho SM, Kim ME, Kim JY, Park JC, Nahm DH. Clinical efficacy of autologous plasma therapy for atopic dermatitis. *Dermatology* 2014; 228: 71-77.
- E46. Choi IH, Kim S, Kim Y, Yun Y. The effect of TJ-15 plus TJ-17 on atopic dermatitis: a pilot study based on the principle of pattern identification. *J Altern Complement Med* 2012; 18: 576-582.
- E47. Chung BY, Kim HO, Kim JH, Cho SI, Lee CH, Park CW. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. *Br J Dermatol* 2013; 168: 908-910.
- E48. Chung BY, Kim JH, Cho SI, Ahn IS, Kim HO, Park CW, et al. Dose-dependent effects of evening primrose oil in children and adolescents with atopic dermatitis. *Ann Dermatol* 2013; 25: 285-291.
- E49. Coenraads PJ, Span L, Jaspers JP, Fidler V. [Intensive patient education and treatment program for young adults with atopic eczema]. *Hautarzt* 2001; 52: 428-433.
- E50. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. *J Am Acad Dermatol* 2000; 42: 653-659.
- E51. De Belilovsky C, Roo-Rodriguez E, Baudouin C, Menu F, Chadoutaud B, Msika P. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. *J Dermatolog Treat* 2011; 22: 359-365.
- E52. De Waure C, Cadeddu C, Venditti A, Barcella A, Bigardi A, Masci S, et al. Non steroid treatment for eczema: results from a controlled and randomized study. *G Ital Dermatol Venereol* 2013; 148: 471-477.
- E53. Del Rosso JQ. An investigator-blinded evaluation of fluocinonide 0.1% cream in the treatment of atopic dermatitis and psoriasis vulgaris. *Cosmet Dermatol* 2007; 20: 545-552.
- E54. Del Rosso JQ, Bhambrani S. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. *J Clin*

- Aesthet Dermatol 2009; 2: 24-32.
- E55. Der-Petrossian M, Seeber A, Honigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. *Br J Dermatol* 2000; 142: 39-43.
- E56. Diepgen TL, Early Treatment of the Atopic Child Study G. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatr Allergy Immunol* 2002; 13: 278-286.
- E57. Dittmar HC, Pflieger D, Schopf E, Simon JC. [UVA1 phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis]. *Hautarzt* 2001; 52: 423-427.
- E58. Dolle S, Hoser D, Rasche C, Loddenkemper C, Maurer M, Zuberbier T, et al. Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. *Allergy* 2010; 65: 1158-1165.
- E59. Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. *Pediatr Allergy Immunol* 2010; 21: 321-329.
- E60. Doss N, Reitamo S, Dubertret L, Fekete GL, Kamoun MR, Lahfa M, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. *Br J Dermatol* 2009; 161: 427-434.
- E61. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. *J Am Acad Dermatol* 2005; 53: 602-609.
- E62. Draelos ZD. An evaluation of prescription device moisturizers. *J Cosmet Dermatol* 2009; 8: 40-43.
- E63. Draelos ZD. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. *J Cosmet Dermatol* 2011; 10: 185-188.
- E64. Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. *Int J Immunopathol Pharmacol* 2011; 24: 1037-1048.
- E65. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. *J Am Acad Dermatol* 2002; 46: 495-504.
- E66. Eichenfield LF, Miller BH, Cutivate Lotion Study G. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. *J Am Acad Dermatol* 2006; 54: 715-717.
- E67. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr* 2013; 172: 351-356.
- E68. Emer JJ, Frankel A, Sohn A, Lebowitz M. A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis. *J Drugs Dermatol* 2011; 10: 735-743.
- E69. Evangelista MT, Abad-Casintahan F, Lopez-Villafuerte L. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial. *Int J Dermatol* 2014; 53: 100-108.
- E70. Farina S, Gisondi P, Zanoni M, Pace M, Rizzoli L, Baldo E, et al. Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. *J Dermatolog Treat* 2011; 22: 366-371.
- E71. Foelster-Holst R, Reitamo S, Yankova R, Worm M, Kadurina M, Thaci D, et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study. *Allergy* 2010; 65: 1594-1599.
- E72. Foelster-Holst R, Nagel F, Zoellner P, Spaeth D. Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis. *Dermatology* 2006; 212: 66-69.
- E73. Folster-Holst R, Muller F, Schnopp N, Abeck D, Kreislermaier I, Lenz T, et al. Prospective, randomized controlled trial on *Lactobacillus rhamnosus* in infants with moderate to severe atopic dermatitis. *Br J Dermatol* 2006; 155: 1256-1261.
- E74. Fontanini C, Berti I, Monasta L, Longo G. DermaSilk in long-term control of infantile atopic dermatitis: a double blind randomized controlled trial. *G Ital Dermatol Venereol* 2013; 148: 293-297.
- E75. Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. *Cutis* 2007; 79: 65-72.
- E76. Frankel A, Sohn A, Patel RV, Lebowitz M. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. *J Drugs Dermatol* 2011; 10: 666-672.
- E77. Friedmann PS, Palmer R, Tan E, Ogboli M, Barclay G, Hotchkiss K, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. *Clin Exp Allergy* 2007; 37: 1536-1540.
- E78. Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K. Effects of a short-term parental education program on childhood atopic dermatitis: a randomized controlled trial. *Pediatr Dermatol* 2013; 30: 438-443.
- E79. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. *Br J Dermatol* 2009; 160: 652-658.
- E80. Gandy JJ, Snyman JR, van Rensburg CE. Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema. *Clin Cosmet Investig Dermatol* 2011; 4: 145-148.
- E81. Gauger A, Fischer S, Mempel M, Schaefer T, Foelster-Holst R, Abeck D, et al. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. *J Eur Acad Dermatol Venereol* 2006; 20: 534-541.
- E82. Gerasimov SV, Vasjuta VV, Myhovyeh OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. *Am J Clin Dermatol* 2010; 11: 351-361.
- E83. Giordano-Labadie F, Cambazard F, Guillet G, Combemale P, Menegeaud V. Evaluation of a new moisturizer (Exomega

- milk) in children with atopic dermatitis. *J Dermatolog Treat* 2006; 17: 78-81.
- E84. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? *Pediatr Allergy Immunol* 2009; 20: 59-66.
- E85. Gøbel RJ, Larsen NN, Mølgaard C, Jakobsen M, Michaelsen KF. Probiotics to young children with atopic dermatitis: a randomized placebo-controlled trial. *Int J Probiotics Prebiotics* 2010; 5: 53-60.
- E86. Gollnick H, Kaufmann R, Stough D, Heikkilä H, Andriano K, Grinienco A, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. *Br J Dermatol* 2008; 158: 1083-1093.
- E87. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, et al. Skin colonization by *Staphylococcus aureus* in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. *Br J Dermatol* 2006; 155: 680-687.
- E88. Gore C, Custovic A, Tannock GW, Munro K, Kerry G, Johnson K, et al. Treatment and secondary prevention effects of the probiotics *Lactobacillus paracasei* or *Bifidobacterium lactis* on early infant eczema: randomized controlled trial with follow-up until age 3 years. *Clin Exp Allergy* 2012; 42: 112-122.
- E89. Gradman J, Wolthers OD. Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. *Acta Paediatr* 2007; 96: 1233-1237.
- E90. Granlund H, Erkkö P, Remitz A, Langeland T, Helsing P, Nuutinen M, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. *Acta Derm Venereol* 2001; 81: 22-27.
- E91. Granlund H, Remitz A, Kyllönen H, Lauerma AI, Reitamo S. Treatment of lichenified atopic eczema with tacrolimus ointment. *Acta Derm Venereol* 2001; 81: 314-315.
- E92. Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J, Cipamylfline Study G. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamylfline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. *Br J Dermatol* 2002; 147: 299-307.
- E93. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: the impact of an educational intervention. *Pediatr Dermatol* 2006; 23: 428-436.
- E94. Grimalt R, Mengeaud V, Cambazard F, Study Investigators G. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology* 2007; 214: 61-67.
- E95. Gruber C, Wendt M, Sulser C, Lau S, Kulig M, Wahn U, et al. Randomized, placebo-controlled trial of *Lactobacillus rhamnosus* GG as treatment of atopic dermatitis in infancy. *Allergy* 2007; 62: 1270-1276.
- E96. Gueniche A, Hennino A, Goujon C, Dahel K, Bastien P, Martin R, et al. Improvement of atopic dermatitis skin symptoms by *Vitreoscilla filiformis* bacterial extract. *Eur J Dermatol* 2006; 16: 380-384.
- E97. Gueniche A, Knautd B, Schuck E, Volz T, Bastien P, Martin R, et al. Effects of nonpathogenic gram-negative bacterium *Vitreoscilla filiformis* lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. *Br J Dermatol* 2008; 159: 1357-1363.
- E98. Gutgesell C, Heise S, Seubert S, Seubert A, Domhof S, Brunner E, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. *Br J Dermatol* 2001; 145: 70-74.
- E99. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol* 2011; 64: 1074-1084.
- E100. Han Y, Kim B, Ban J, Lee J, Kim BJ, Choi BS, et al. A randomized trial of *Lactobacillus plantarum* CJLP133 for the treatment of atopic dermatitis. *Pediatr Allergy Immunol* 2012; 23: 667-673.
- E101. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol* 2002; 147: 528-537.
- E102. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. *J Am Acad Dermatol* 2001; 44: S28-38.
- E103. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. *Br J Dermatol* 2000; 142: 52-58.
- E104. Hashizume E, Nakano T, Kamimura A, Morishita K. Topical effects of N-acetyl-L-hydroxyproline on ceramide synthesis and alleviation of pruritus. *Clin Cosmet Investig Dermatol* 2013; 6: 43-49.
- E105. Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ, Desonide Hydrogel Study G. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. *J Drugs Dermatol* 2007; 6: 175-181.
- E106. Hebert AA, Koo J, Fowler J, Berman B, Rosenberg C, Levitt J. Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. *Cutis* 2006; 78: 357-363.
- E107. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. *J Dtsch Dermatol Ges* 2010; 8: 990-998.
- E108. Heintlin J, Schiffner-Rohe J, Schiffner R, Einsele-Kramer B, Landthaler M, Klein A, et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. *J Eur Acad Dermatol Venereol* 2011; 25: 765-773.
- E109. Henderson C, Morris A, Wilson A, Ilchyshyn A. An open study comparing the efficacy of two different Chinese herbal therapy formulations in atopic eczema and their effects on circulating activated T-lymphocytes. *J Dermatolog Treat* 2000; 11: 91-96.
- E110. Hennino A, Cornu C, Rozieres A, Augey F, Villard-Truc F, Payot F, et al. Influence of measles vaccination on the progression of atopic dermatitis in infants. *Pediatr Allergy Immunol* 2007; 18: 385-390.
- E111. Herzog JL, Solomon JA, Draelos Z, Fleischer A, Jr., Stough D, Wolf DI, et al. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opioid antagonist nalmeferine in subjects with atopic dermatitis. *J Drugs Dermatol* 2011; 10: 853-860.
- E112. Hindley D, Galloway G, Murray J, Gardener L. A randomised study of "wet wraps" versus conventional treatment for

- atopic eczema. *Arch Dis Child* 2006; 91: 164-168.
- E113. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *J Pediatr* 2003; 142: 155-162.
- E114. Hoeger PH, Lee KH, Jautova J, Wohlrab J, Guettner A, Mizutani G, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. *Br J Dermatol* 2009; 160: 415-422.
- E115. Hon KL, Leung TF, Ng PC, Lam MC, Kam WY, Wong KY, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. *Br J Dermatol* 2007; 157: 357-363.
- E116. Huang JT, Abrams M, Tloughan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics* 2009; 123: e808-814.
- E117. Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, et al. *Staphylococcus* colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. *Ann Allergy Asthma Immunol* 2007; 98: 51-56.
- E118. Iemoli E, Trabattoni D, Parisotto S, Borgonovo L, Toscano M, Rizzardini G, et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol* 2012; 46 Suppl: S33-40.
- E119. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clin Exp Allergy* 2000; 30: 1604-1610.
- E120. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. *Int Arch Allergy Immunol* 2013; 162: 89-93.
- E121. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. *J Am Acad Dermatol* 2000; 42: 1033-1040.
- E122. Januchowski R. Evaluation of topical vitamin B(12) for the treatment of childhood eczema. *J Altern Complement Med* 2009; 15: 387-389.
- E123. Javanbakht MH, Keshavarz SA, Djalali M, Siassi F, Eshraghian MR, Firooz A, et al. Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. *J Dermatolog Treat* 2011; 22: 144-150.
- E124. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis. *Allergy Asthma Immunol Res* 2011; 3: 89-95.
- E125. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. *J Allergy Clin Immunol* 2009; 124: R19-28.
- E126. Jensen JM, Weppner M, Dahnhardt-Pfeiffer S, Neumann C, Brautigam M, Schwarz T, et al. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial. *Acta Derm Venereol* 2013; 93: 515-519.
- E127. Jin YY, Cao RM, Chen J, Kaku Y, Wu J, Cheng Y, et al. Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study. *Pediatr Allergy Immunol* 2011; 22: 688-694.
- E128. Ju M. Study of calcipotriol betamethasone ointment in the treatment of patients with refractory chronic eczema. *Asian Journal of Pharmaceutical and Clinical Research* 2013; 6: 34-40.
- E129. Juenger M, Ladwig A, Staecker S, Arnold A, Kramer A, Daeschlein G, et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). *Curr Med Res Opin* 2006; 22: 739-750.
- E130. Kardorff B, Schnelle-Parker G, Kardorff M, Wahlen M, d'Orville IH, Dorittke P. [Successful reduction of the SCORAD score by a short-time teaching method using a simplified skin model in children with atopic eczema in a 6-week comparison]. *J Dtsch Dermatol Ges* 2003; 1: 451-456.
- E131. Katsuyama M, Ichikawa H, Ogawa S, Ikezawa Z. A novel method to control the balance of skin microflora. Part 1. Attack on biofilm of *Staphylococcus aureus* without antibiotics. *J Dermatol Sci* 2005; 38: 197-205.
- E132. Kaufmann R, Bieber T, Helgesen AL, Andersen BL, Luger T, Poulin Y, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. *Allergy* 2006; 61: 375-381.
- E133. Kaufmann R, Folster-Holst R, Hoger P, Thaci D, Loffler H, Staab D, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. *J Allergy Clin Immunol* 2004; 114: 1183-1188.
- E134. Kawana S, Kato Y, Omi T. Efficacy of a 5-HT<sub>1a</sub> receptor agonist in atopic dermatitis. *Clin Exp Dermatol* 2010; 35: 835-840.
- E135. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol* 2003; 148: 1212-1221.
- E136. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. *J Am Acad Dermatol* 2004; 51: 515-525.
- E137. Kief H. Prospektive, randomisierte Studie zur Wirksamkeit und Verträglichkeit modifizierter Eigenblutbehandlung AHIT®- und konventioneller Eigenblutbehandlung bei Neurodermitis. *Aktuelle Derm* 2007; 33: 216-227.
- E138. Kim DH, Lee HJ, Park CW, Kim KH, Lee KH, Ro BI, et al. The Clinical Efficacy of Mometasone Furoate in Multi-Lamellar Emulsion for Eczema: A Double-Blinded Crossover Study. *Ann Dermatol* 2013; 25: 17-22.
- E139. Kim SH, Hwang SH, Hong SK, Seo JK, Sung HS, Park SW, et al. The clinical efficacy, safety and functionality of anion textile in the treatment of atopic dermatitis. *Ann Dermatol* 2012; 24: 438-443.
- E140. Kimata H. Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide. *Pediatr Dermatol* 2006; 23: 386-389.
- E141. Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream. *J Dermatolog Treat* 2003; 14: 141-148.
- E142. Klovekorn W, Tepe A, Danesch U. A randomized, double-blind, vehicle-controlled, half-side comparison with a herbal

- ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica for the treatment of mild-to-moderate atopic dermatitis. *Int J Clin Pharmacol Ther* 2007; 45: 583-591.
- E143. Kobayashi H, Ishii M, Takeuchi S, Tanaka Y, Shintani T, Yamatodani A, et al. Efficacy and Safety of a Traditional Herbal Medicine, Hochu-ekki-to in the Long-term Management of Kikyo (Delicate Constitution) Patients with Atopic Dermatitis: A 6-month, Multicenter, Double-blind, Randomized, Placebo-controlled Study. *Evid Based Complement Alternat Med* 2010; 7: 367-373.
- E144. Koch C, Dolle S, Metzger M, Rasche C, Jungclas H, Ruhl R, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. *Br J Dermatol* 2008; 158: 786-792.
- E145. Koller DY, Halmerbauer G, Bock A, Engstler G. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. *Pediatr Allergy Immunol* 2007; 18: 335-338.
- E146. Korting HC, Schollmann C, Cholcha W, Wolff L, Collaborative Study G. Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. *J Eur Acad Dermatol Venereol* 2010; 24: 1176-1182.
- E147. Kwon HB, Ahn BJ, Choi Y, Jin SY, Cheong KA, Lee J, et al. Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: a pilot study. *J Dermatol* 2013; 40: 207-210.
- E148. Larsen FS, Simonsen L, Melgaard A, Wendicke K, Henriksen AS. An efficient new formulation of fusidic acid and beta-methasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. *Acta Derm Venereol* 2007; 87: 62-68.
- E149. Lee J, Jung E, Koh J, Kim YS, Park D. Effect of rosmarinic acid on atopic dermatitis. *J Dermatol* 2008; 35: 768-771.
- E150. Lee KC, Keyes A, Hensley JR, Gordon JR, Kwasny MJ, West DP, et al. Effectiveness of acupressure on pruritus and lichenification associated with atopic dermatitis: a pilot trial. *Acupunct Med* 2012; 30: 8-11.
- E151. Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. *J Allergy Clin Immunol* 2004; 114: 691-693.
- E152. Leung DY, Hanifin JM, Pariser DM, Barber KA, Langley RG, Schlievert PM, et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. *Br J Dermatol* 2009; 161: 435-443.
- E153. Leung TF, Ma KC, Cheung LT, Lam CW, Wong E, Wan H, et al. A randomized, single-blind and crossover study of an amino acid-based milk formula in treating young children with atopic dermatitis. *Pediatr Allergy Immunol* 2004; 15: 558-561.
- E154. Ling M, Gottlieb A, Pariser D, Caro I, Stewart D, Scott G, et al. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. *J Dermatolog Treat* 2005; 16: 142-148.
- E155. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. *Allergy* 2001; 56: 512-517.
- E156. Loden M, Andersson AC, Anderson C, Bergbrant IM, Frodin T, Ohman H, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. *Acta Derm Venereol* 2002; 82: 45-47.
- E157. Loden M, Andersson AC, Andersson C, Frodin T, Oman H, Lindberg M. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. *Skin Res Technol* 2001; 7: 209-213.
- E158. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. *Br J Dermatol* 2001; 144: 788-794.
- E159. Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. *J Dermatolog Treat* 2004; 15: 169-178.
- E160. Majoie IM, Oldhoff JM, van Weelden H, Laaper-Ertmann M, Bousema MT, Sigurdsson V, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. *J Am Acad Dermatol* 2009; 60: 77-84.
- E161. Malekzad F, Arbabi M, Mohtasham N, Toosi P, Jaberian M, Mohajer M, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. *J Eur Acad Dermatol Venereol* 2009; 23: 948-950.
- E162. Mandelin J, Remitz A, Virtanen H, Reitamo S. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. *Acta Derm Venereol* 2010; 90: 170-174.
- E163. Marini A, Reinelt K, Krutmann J, Bilstein A. Ectoïne-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. *Skin Pharmacol Physiol* 2014; 27: 57-65.
- E164. Matheson R, Kempers S, Breneman D, Draelos Z, Johnson CE, Loss R, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. *J Drugs Dermatol* 2008; 7: 266-271.
- E165. Mayser P, Kupfer J, Nemetz D, Schafer U, Nilles M, Hort W, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream--results of a double-blind, placebo-controlled study. *Skin Pharmacol Physiol* 2006; 19: 153-158.
- E166. Mayser P, Mayer K, Mahloudjian M, Benzing S, Kramer HJ, Schill WB, et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. *JPEN J Parenter Enteral Nutr* 2002; 26: 151-158.
- E167. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet* 2006; 367: 839-846.
- E168. Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. *J Dermatolog Treat* 2010; 21: 157-166.
- E169. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology* 2002; 205: 271-277.

- E170. Miller DW, Koch SB, Yentzer BA, Clark AR, O'Neill JR, Fountain J, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. *J Drugs Dermatol* 2011; 10: 531-537.
- E171. Moore EJ, Williams A, Manias E, Varigos G, Donath S. Eczema workshops reduce severity of childhood atopic eczema. *Australas J Dermatol* 2009; 50: 100-106.
- E172. Mora R, Bellussi L, Passali FM, Crippa B, Mora F, Cordone MP, et al. Efficacy of a topical suspension of bacterial antigens for the management of recurrent eczema in children. *Med Sci Monit* 2004; 10: PI99-PI103.
- E173. Moroi M, Uchi S, Nakamura K, Sato S, Shimizu N, Fujii M, et al. Beneficial effect of a diet containing heat-killed *Lactobacillus paracasei* K71 on adult type atopic dermatitis. *J Dermatol* 2011; 38: 131-139.
- E174. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. *Pediatr Dermatol* 2008; 25: 606-612.
- E175. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiedzinski Z, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. *Dermatology* 2002; 205: 40-45.
- E176. Murrell DF, Calvieri S, Ortonne JP, Ho VC, Weise-Riccardi S, Barbier N, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. *Br J Dermatol* 2007; 157: 954-959.
- E177. Nermes M, Kantele JM, Atosuo TJ, Salminen S, Isola E. Interaction of orally administered *Lactobacillus rhamnosus* GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. *Clin Exp Allergy* 2011; 41: 370-377.
- E178. Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. *J Dtsch Dermatol Ges* 2008; 6: 548-553.
- E179. Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. *Eye (Lond)* 2007; 21: 968-975.
- E180. Novak N, Bieber T, Hoffmann M, Folster-Holst R, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. *J Allergy Clin Immunol* 2012; 130: 925-931 e924.
- E181. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. *Allergy* 2005; 60: 693-696.
- E182. Oosting AJ, de Bruin-Weller MS, Terreehorst I, Tempels-Pavlica Z, Aalberse RC, de Monchy JG, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. *J Allergy Clin Immunol* 2002; 110: 500-506.
- E183. Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. *Clin Exp Allergy* 2004; 34: 639-645.
- E184. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. *J Allergy Clin Immunol* 2007; 120: 164-170.
- E185. Paller AS, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. *J Am Acad Dermatol* 2001; 44: S47-57.
- E186. Paller AS, Lebwohl M, Fleischer AB, Jr., Antaya R, Langley RG, Kirsner RS, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. *J Am Acad Dermatol* 2005; 52: 810-822.
- E187. Paller AS, Nimmagadda S, Schachner L, Mallory SB, Kahn T, Willis I, et al. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. *J Am Acad Dermatol* 2003; 48: 569-577.
- E188. Palombo P, Morganti P, Fabrizi G, GUAMERI F, Valenzano F, FENG XZ. A special pill-mask to re-hydrate the skin affected by atopic dermatitis. *Journal of applied cosmetology* 2004; 22: 87-97.
- E189. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. *Allergy* 2006; 61: 431-437.
- E190. Patrizi A, Capitanio B, Neri I, Giacomini F, Sinagra JL, Raone B, et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. *Pediatr Allergy Immunol* 2008; 19: 619-625.
- E191. Patrizi A, Raone B, Raboni R, Neri I. Efficacy and tolerability of a cream containing AR-GG27(R) (sorbityl furfural palmitate) in the treatment of mild/moderate childhood atopic dermatitis associated with pityriasis alba. A double-blind, placebo-controlled clinical trial. *G Ital Dermatol Venereol* 2012; 147: 1-8.
- E192. Patzelt-Wenczler R, Ponce-Poschl E. Proof of efficacy of Kamillolan(R) cream in atopic eczema. *Eur J Med Res* 2000; 5: 171-175.
- E193. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. *Br J Dermatol* 2002; 147: 518-522.
- E194. Pei AY, Chan HH, Ho KM. The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. *Pediatr Dermatol* 2001; 18: 343-348.
- E195. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. *Pediatr Allergy Immunol* 2001; 12: 154-158.
- E196. Pellanda C, Weber M, Bircher A, Surber C. Low-dose triamcinolone acetonide in the phytocosmetic lichtenal reduces inflammation in mild to moderate atopic dermatitis. *Dermatology* 2005; 211: 338-340.
- E197. Peserico A, Stadler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre,

- randomized, double-blind, controlled study. *Br J Dermatol* 2008; 158: 801-807.
- E198. Pfäb F, Athanasiadis GI, Huss-Marp J, Fuqin J, Heuser B, Cifuentes L, et al. Effect of acupuncture on allergen-induced basophil activation in patients with atopic eczema: a pilot trial. *J Altern Complement Med* 2011; 17: 309-314.
- E199. Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. *Br J Dermatol* 2003; 148: 307-313.
- E200. Prado do Oliveira Z, Cuce L, Arnone M. Comparative evaluation of efficacy, tolerability and safety of 0.1% topical mometasone furoate and 0.05% desonide in the treatment of childhood atopic dermatitis. *Anais Brasileiros de Dermatologia* 2002; 77: 25-33.
- E201. Rahman M. Efficacy of topical tacrolimus in atopic dermatitis. *Journal of Pakistan Association of Dermatologists* 2008; 18: 84-92.
- E202. Rahman ML, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. *Mymensingh Med J* 2006; 15: 85-88.
- E203. Ramirez-Bosca A, Zapater P, Betlloch I, Alberio F, Martinez A, Diaz-Alperi J, et al. Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial. *Actas Dermosifiliogr* 2012; 103: 599-607.
- E204. Ravenscroft JC, Layton AM, Eady EA, Murtagh MS, Coates P, Walker M, et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) *Staphylococcus aureus* in atopic eczema. *Br J Dermatol* 2003; 148: 1010-1017.
- E205. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. *Br J Dermatol* 2004; 150: 554-562.
- E206. Reitamo S, Mandelin J, Rubins A, Remitz A, Makela M, Cirule K, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. *Int J Dermatol* 2009; 48: 348-355.
- E207. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol* 2005; 152: 1282-1289.
- E208. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. *J Allergy Clin Immunol* 2002; 109: 547-555.
- E209. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. *J Allergy Clin Immunol* 2002; 109: 539-546.
- E210. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. *Lancet* 2001; 357: 2012-2016.
- E211. Ricci G, Patrizi A, Specchia F, Menna L, Bottau P, D'Angelo V, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. *Br J Dermatol* 2000; 143: 379-384.
- E212. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol* 2003; 111: 389-395.
- E213. Ruer-Mulard M, Aberer W, Gunstone A, Kekki OM, Lopez Esteban JL, Vertruyen A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. *Pediatr Dermatol* 2009; 26: 551-558.
- E214. Ruzicka T, Willers C, Wigger-Alberti W. Efficacy and patient-reported outcomes of a new mometasone cream treating atopic eczema. *Skin Pharmacol Physiol* 2012; 25: 305-312.
- E215. Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of atopic dermatitis with licorice gel. *J Dermatolog Treat* 2003; 14: 153-157.
- E216. Sagransky MJ, Yentzer BA, Williams LL, Clark AR, Taylor SL, Feldman SR. A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. *Arch Dermatol* 2010; 146: 1428-1430.
- E217. Saki N, Jowkar F, Alyaseen S. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis. *J Dermatolog Treat* 2013; 24: 447-449.
- E218. Sanchez Caraballo JM, Cardona Villa R. Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: randomized controlled trial. *ISRN Allergy* 2012; 2012: 183983.
- E219. Santer M, Muller I, Yardley L, Burgess H, Selinger H, Stuart BL, et al. Supporting self-care for families of children with eczema with a Web-based intervention plus health care professional support: pilot randomized controlled trial. *J Med Internet Res* 2014; 16: e70.
- E220. Schempp CM, Hezel S, Simon JC. [Topical treatment of atopic dermatitis with Hypericum cream. A randomised, placebo-controlled, double-blind half-side comparison study]. *Hautarzt* 2003; 54: 248-253.
- E221. Schlessinger J, Miller B, Gilbert RD, Plott RT, Vanos Study G. An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. *Arch Dermatol* 2006; 142: 1568-1572.
- E222. Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. *Br J Dermatol* 2010; 162: 661-668.
- E223. Schnopp C, Holtmann C, Stock S, Remling R, Folster-Holst R, Ring J, et al. Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial. *Dermatology* 2002; 204: 56-59.
- E224. Schram ME, Roekevisch E, Leeftang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *J Allergy Clin Immunol* 2011; 128: 353-359.
- E225. Schut C, Weik U, Tews N, Gieler U, Deinzer R, Kupfer J. Psychophysiological effects of stress management in patients with atopic dermatitis: a randomized controlled trial. *Acta Derm Venereol* 2013; 93: 57-61.
- E226. Schuttelaar ML, Coenraads PJ. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. *J Eur Acad Dermatol Venereol* 2008; 22: 1076-1082.



- E227. Schuttelaar ML, Vermeulen KM, Drukker N, Coenraads PJ. A randomized controlled trial in children with eczema: nurse practitioner vs. dermatologist. *Br J Dermatol* 2010; 162: 162-170.
- E228. Selvaag E, Caspersen L, Bech-Thomsen N, Wulf HC. Optimized UVB treatment of atopic dermatitis using skin reflectance measurements. A controlled, left-right comparison trial. *Acta Derm Venereol* 2005; 85: 144-146.
- E229. Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial. *Indian J Dermatol Venereol Leprol* 2008; 74: 447-452.
- E230. Sencer C. Hypnotherapie bei atopischer Dermatitis. *Aktuelle Derm* 2004; 30: 108.
- E231. Shafiei A, Moin M, Pourpak Z, Gharagozlou M, Aghamohammadi A, Sajedi V, et al. Synbiotics could not reduce the scoring of childhood atopic dermatitis (SCORAD): a randomized double blind placebo-controlled trial. *Iran J Allergy Asthma Immunol* 2011; 10: 21-28.
- E232. Shapira MY, Raphaelovich Y, Gilad L, Or R, Dumb AJ, Ingber A. Treatment of atopic dermatitis with herbal combination of *Eleutherococcus*, *Achillea millefolium*, and *Lamium album* has no advantage over placebo: a double blind, placebo-controlled, randomized trial. *J Am Acad Dermatol* 2005; 52: 691-693.
- E233. Shaw M, Morrell DS, Goldsmith LA. A study of targeted enhanced patient care for pediatric atopic dermatitis (STEP PAD). *Pediatr Dermatol* 2008; 25: 19-24.
- E234. Shibata R, Kimura M, Takahashi H, Mikami K, Aiba Y, Takeda H, et al. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. *Clin Exp Allergy* 2009; 39: 1397-1403.
- E235. Sidbury R, Sullivan AF, Thadhani RI, Camargo CA, Jr. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. *Br J Dermatol* 2008; 159: 245-247.
- E236. Siebenwirth J, Ludtke R, Remy W, Rakoski J, Borelli S, Ring J. [Effectiveness of a classical homeopathic treatment in atopic eczema. A randomised placebo-controlled double-blind clinical trial]. *Forsch Komplementmed* 2009; 16: 315-323.
- E237. Sigurgeirsson B, Ho V, Ferrandiz C, Andriano K, Grinienko A, Jimenez P, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. *J Eur Acad Dermatol Venereol* 2008; 22: 1290-1301.
- E238. Simpson E, Bohling A, Bielfeldt S, Bosc C, Kerrouche N. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. *J Dermatolog Treat* 2013; 24: 122-125.
- E239. Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. *J Drugs Dermatol* 2011; 10: 744-749.
- E240. Sistek D, Kelly R, Wickens K, Stanley T, Fitzharris P, Crane J. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? *Clin Exp Allergy* 2006; 36: 629-633.
- E241. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ* 2006; 332: 933-938.
- E242. Staab D, von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. *Pediatr Allergy Immunol* 2002; 13: 84-90.
- E243. Stainer R, Matthews S, Arshad SH, McDonald S, Robinson J, Schapira C, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. *Br J Dermatol* 2005; 152: 334-341.
- E244. Stern T, Bayerl C. Schwarzkümmelöl-Salbe, eine neue Möglichkeit der topischen Behandlung des atopischen Ekzems? *Akt Dermatol* 2002; 28: 74-79.
- E245. Stinco G, Piccirillo F, Valent F. A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. *Dermatology* 2008; 217: 191-195.
- E246. Stucker M, Pieck C, Stoerb C, Niedner R, Hartung J, Altmeyer P. Topical vitamin B12--a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. *Br J Dermatol* 2004; 150: 977-983.
- E247. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. *J Drugs Dermatol* 2009; 8: 1106-1111.
- E248. Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. *J Eur Acad Dermatol Venereol* 2004; 18: 445-449.
- E249. Takeuchi S, Saeki H, Tokunaga S, Sugaya M, Ohmatsu H, Tsunemi Y, et al. A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritus in patients with atopic dermatitis. *Ann Dermatol* 2012; 24: 144-150.
- E250. Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, et al. Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial. *BMJ* 2003; 327: 1385.
- E251. Tan WP, Suresh S, Tey HL, Chiam LY, Goon AT. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. *Clin Exp Dermatol* 2010; 35: e109-112.
- E252. Taniuchi S. Administration of Bifidobacterium to Infants with Atopic Dermatitis: Changes in Fecal Microflora and Clinical Symptoms. *J Appl Res* 2005; 5: 387-396.
- E253. Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *Br J Dermatol* 2008; 159: 1348-1356.
- E254. Thomas KS, Armstrong S, Avery A, Po AL, O'Neill C, Young S, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. *BMJ* 2002; 324: 768.
- E255. Thomas KS, Dean T, O'Leary C, Sach TH, Koller K, Frost A, et al. A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children. *PLoS Med* 2011; 8: e1000395.
- E256. Thumm EJ. Überprüfung der Wirksamkeit einer 20%igen und 10%igen Sanddornkernölcreme bei Patienten mit leichter bis mittelgradiger atopischer Dermatitis. *Aktuelle Dermatologie* 2000; 26: 285.

- E257. Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral administration of *Lactobacillus acidophilus* L-92 on the symptoms and serum markers of atopic dermatitis in children. *Int Arch Allergy Immunol* 2011; 154: 236-245.
- E258. Tripodi S, Di Rienzo Businco A, Panetta V, Pingitore G, Volterrani A, Frediani T, et al. Lack of efficacy of topical furfuryl palmitate in pediatric atopic dermatitis: a randomized double-blind study. *J Investig Allergol Clin Immunol* 2009; 19: 204-209.
- E259. Trookman NS, Rizer RL. Randomized Controlled Trial of Desonlde Hydrogel 0.05% versus Desonide Ointment 0.05% in the Treatment of Mild-to-moderate Atopic Dermatitis. *J Clin Aesthet Dermatol* 2011; 4: 34-38.
- E260. Tzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Honigsman H, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. *Br J Dermatol* 2010; 162: 655-660.
- E261. Tzung TY, Lin CB, Chen YH, Yang CY. Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. *Acta Derm Venereol* 2006; 86: 34-38.
- E262. Ucak H, Demir B, Cicek D, Dertlioglu SB, Akkurt ZM, Ucmak D, et al. Efficacy of topical tacrolimus for the treatment of persistent pruritus ani in patients with atopic dermatitis. *J Dermatolog Treat* 2013; 24: 454-457.
- E263. Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. *J Eur Acad Dermatol Venereol* 2011; 25: 660-665.
- E264. Valkova S, Velkova A. UVA/UVB phototherapy for atopic dermatitis revisited. *J Dermatolog Treat* 2004; 15: 239-244.
- E265. van der Aa LB, Heymans HS, van Aalderen WM, Sillevius Smitt JH, Knol J, Ben Amor K, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. *Clin Exp Allergy* 2010; 40: 795-804.
- E266. van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, van der Zalm A, de Bruin-Weller MS, Pasmans SG, et al. E-health in caring for patients with atopic dermatitis: a randomized controlled cost-effectiveness study of internet-guided monitoring and online self-management training. *Br J Dermatol* 2012; 166: 1060-1068.
- E267. Veien NK, Busch-Sorensen M, Stausbol-Gron B. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol* 2005; 53: 147-149.
- E268. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. *Allergy* 2005; 60: 494-500.
- E269. Vita D, Passalacqua G, Di Pasquale G, Caminiti L, Crisafulli G, Rulli I, et al. Ass's milk in children with atopic dermatitis and cow's milk allergy: crossover comparison with goat's milk. *Pediatr Allergy Immunol* 2007; 18: 594-598.
- E270. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics* 2002; 110: e2.
- E271. Wananukul S, Chatproedprai S, Chunharas A, Limpongsanuruk W, Singalavanija S, Nitiyaron R, et al. Randomized, double-blind, split-side, comparison study of moisturizer containing licochalcone A and 1% hydrocortisone in the treatment of childhood atopic dermatitis. *J Med Assoc Thai* 2013; 96: 1135-1142.
- E272. Weber MB, Fontes Neto Pde T, Prati C, Soirefman M, Mazzotti NG, Barzenski B, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. *J Eur Acad Dermatol Venereol* 2008; 22: 992-997.
- E273. Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. *J Eur Acad Dermatol Venereol* 2009; 23: 1267-1272.
- E274. Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. *Br J Dermatol* 2005; 152: 1296-1303.
- E275. Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. *Allergy* 2008; 63: 742-750.
- E276. Wong AW, Hon EK, Zee B. Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control. *Int J Dermatol* 2008; 47: 187-191.
- E277. Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. *J Dermatol* 2013; 40: 874-880.
- E278. Woo SI, Kim JY, Lee YJ, Kim NS, Hahn YS. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann Allergy Asthma Immunol* 2010; 104: 343-348.
- E279. Woods MT, Brown PA, Baig-Lewis SF, Simpson EL. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. *J Drugs Dermatol* 2011; 10: 171-176.
- E280. Wu KG, Li TH, Peng HJ. *Lactobacillus salivarius* plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. *Br J Dermatol* 2012; 166: 129-136.
- E281. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. *Br J Dermatol* 2013; 168: 172-178.
- E282. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. *J Am Acad Dermatol* 2001; 44: 89-93.
- E283. Yang B, Kalimo KO, Tahvonen RL, Mattila LM, Katajisto JK, Kallio HP. Effect of dietary supplementation with sea buckthorn (*Hippophae rhamnoides*) seed and pulp oils on the fatty acid composition of skin glycerophospholipids of patients with atopic dermatitis. *J Nutr Biochem* 2000; 11: 338-340.
- E284. Yesilova Y, Calka O, Akdeniz N, Berktaş M. Effect of probiotics on the treatment of children with atopic dermatitis. *Ann Dermatol* 2012; 24: 189-193.
- E285. Yokoyama Y, Kimata H, Mitarai S, Hirano S, Shirakawa T. Ethylene vinyl alcohol (EVOH) fiber compared to cotton underwear in the treatment of childhood atopic dermatitis: a double-blind randomized study. *Indian Pediatr* 2009; 46: 611-614.
- E286. Yoshida Y. Clinical Effects of Probiotic *Bifidobacterium breve* Supplementation in Adult Patients with Atopic Dermatitis. *Yonago Acta med* 2010; 53: 37-45.

- E287. Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Brautigam M. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. *Dermatology* 2007; 215: 325-330.
- E288. Alex P, Payne A, Desai A, Centola M, Thomas S, Yesudas T. HAT-01, a novel herbal preparation, is superior to corticosteroids and pimecrolimus for the treatment of moderate to severe atopic dermatitis. *J Am Acad Dermatol* 2013; 68: AB76-AB76.
- E289. Barba JF. Pimecrolimus cream 1% is effective, well tolerated and safe in infants/children with atopic eczema of the face. *J Eur Acad Dermatol Venereol* 2003; 17: 182.
- E290. Bautista LC. The effects of fish oil supplementation on serum levels of interleukin 10 and total immunoglobulin E among pediatric patients with atopic dermatitis: a randomized controlled single blind clinical trial. *Ann Allergy Asthma Immunol* 2010; 105: A126.
- E291. Beck LA. Systemic treatment of patients with severe atopic dermatitis (AD) with an anti IL-4R $\alpha$  mAb (REGN668/SAR231893) results in rapid and sustained improvements in disease signs and symptoms. *J Invest Dermatol* 2013; 133: S178.
- E292. Beutner K, Jones T, Bucko A, Loss R. A randomized, double-blind, vehicle-controlled, multi-center study to evaluate the safety and efficacy of topically applied AN0128 cream, 1% for the treatment of mild to moderate atopic dermatitis. *J Am Acad Dermatol* 2007; 56: AB72-AB72.
- E293. Bieber T. Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study. *J Allergy Clin Immunol* 2014; 133: AB404.
- E294. Bishop M, Vukovic-Wysocki I, Qaundah P, Poulin Y. A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: clinical safety. *J Am Acad Dermatol* 2011; 64: AB56-AB56.
- E295. Bostoen J, Geusens B, Bracke S, Dekeyser S, Lambert J. Follow-up on the effect of a patient educational programme: early results of a prospective randomized controlled trial in psoriasis and atopic dermatitis. *Br J Dermatol* 2011; 165: E34-E35.
- E296. Brautigam M, Meurer M. Steroid-sparing potential of pimecrolimus cream 1% in the long-term management of severe atopic eczema in adults. *J Am Acad Dermatol* 2006; 54: AB83-AB83.
- E297. Craig TJ, Correale C, Chinchilli V, Lehman E, Mende C, Longenecker A, et al. The effects of montelukast on atopic dermatitis (AD): A placebo-controlled, double-blind, parallel study. *J Allergy Clin Immunol* 2002; 109: S160.
- E298. Cukrowska B, Ceregra A, Rosiak I, Klewicka E, Slizewska K, Motyl I. The influence of probiotic *Lactobacillus casei* and *paracasei* strains on clinical status of atopic eczema in children with food allergy on cow's milk proteins. *Pediatr Współcz* 2008; 10: 67-70.
- E299. Del Rosso J, Bikowski J, Hawkes S, Sanglay L. A double-blind, randomized comparative assessment of efficacy and skin tolerability in patients using either a branded wash versus a soap-based cleanser. *J Am Acad Dermatol* 2006; 54: AB64-AB64.
- E300. Dou X, Liu L-l, Xie Z-q, Chen L, Li L, Feng S, et al. The impact of tacrolimus ointment on health-related quality of life of Chinese adult and pediatric patients with atopic dermatitis. *Journal of Clinical Dermatology* 2006; 35: 50.
- E301. Estrada A, Ramirez E, Toledo M, Galicia J, Estrada-Garcia I, Jimenez-Martinez M, et al. Metilprednisolone and dialyzable leukocytes extracts induce changes in frequency of CLA $^+$  T cells in patients with atopic dermatitis (P4196). *J Immunol* 2013; 190: 48.48.
- E302. Farid R, Jabbari F, Ahanchian H, Moghiman T. Clinical and immunological Effect of Probiotic in childhood Atopic Dermatitis. *J Allergy Clin Immunol* 2010; 125: AB93.
- E303. Fleischer A, Johnson K. Comparative efficacy and patient preference of 1% pramoxine lotion and 1% hydrocortisone cream in reducing pruritus in mild atopic dermatitis. *J Am Acad Dermatol* 2006; 54: AB88-AB88.
- E304. Freeman S, Day R, Williams K, Liauw W. A new treatment for atopic dermatitis: a randomized double-blind placebo-controlled study. *J Am Acad Dermatol* 2006; 54: AB3-AB3.
- E305. Friedlander S, Loss R, Schlessinger J, Potts A. A phase 3 double-blind, randomized, vehicle-controlled study of desonide foam in pediatric and adolescent patients with mild to moderate atopic dermatitis. *J Am Acad Dermatol* 2006; 54: AB85-AB85.
- E306. Fukuie T, Matsumoto K, Narita M, Nomura I, Tokura Y, Ohya Y. Does proactive management of atopic dermatitis affect sensitization or tolerance? A randomized controlled study. *Allergy* 2013; 68: 37-37.
- E307. Galicia Carreon J, Ramirez Cortes E, Toledo Bahena M, Ramirez I, Robledo Avila F, Velasco Velazquez M, et al. Randomized, double-blind trial of topical methylprednisolone combined with oral dialyzable leukocyte extract in patients with moderate atopic dermatitis. *Immunology* 2013; 140: 147-147.
- E308. Ghanei N, Siassi F, Zandieh F, Rahimi A, رفیس ایس، ن عیاق، et al. Effectiveness of prebiotic in atopic dermatitis reduction in 7-24 months old children living in Isfahan. *Journal of Isfahan Medical School* 2011; 28.
- E309. Griffiths C, Gibbs N. Therapeutic Potential of Oral L-Histidine in Atopic Dermatitis. *J Invest Dermatol* 2012; 132: S51-S51.
- E310. Gromert N, Axelsson I. *Lactobacillus reuteri* effect on atopic eczema in childhood. *J Pediatr Gastroenterol Nutr* 2009; 48: E148-149.
- E311. Gupta A. Efficacy of fluocinonide 0.1% cream in the treatment of atopic dermatitis. *J Am Acad Dermatol* 2006; 54: AB86.
- E312. Hamada M, Gyoutoku T, Sato S, Matsuda T, Kinukawa N, et al. The Usefulness of Camellia Oil Spray for Treatment of Atopic Dermatitis. *Nishi Nihon Hifuka* 2008; 70: 213-218.
- E313. Hattori K, Yamamoto A, Sasai M, Taniuchi S, Kojima T, Kobayashi Y, et al. [Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis]. *Arerugi* 2003; 52: 20-30.
- E314. Hoey S, Catney D, Maguire S, McKenna K. Fixed low dose versus increasing dose of ultraviolet B-TL01 in the treatment of atopic eczema. *Br J Dermatol* 2006; 155: 121-122.
- E315. Hosokawa C, Uchi H, Moroi Y, Furue M, Hamada M. Evaluation of a Low-irritant Washcloth for Patients with Atopic Dermatitis. *Nishi Nihon Hifuka* 2008; 70: 442-444.
- E316. Ivakhnenko O, Niankovskyy S. [Clinical effectiveness of probiotics in complex treatment of infants with cow's milk allergy]. *Georgian Med News* 2013; 39-45.
- E317. Katz H, Boeck C, Lin T, Abrams K, Olin J. Low skin thinning potential of pimecrolimus cream versus triamcinolone cream on otherwise normal forehead target area skin in adults with a history of atopic dermatitis. *J Invest Dermatol* 2012; 132: S89-S89.

- E318. Kawashima M, Nakagawa H. Olopatadine Hydrochloride in Children : Evidenced Efficacy and Safety for Atopic Dermatitis Treatment in a Randomized, Multicenter, Double-blind, Parallel Group Comparative Study. *Nishi Nihon Hifuka* 2011; 73: 278-289.
- E319. Kim H, Jeong S, Bae J, Kwon M, Lee S. Therapeutic efficacy of defensamide in atopic dermatitis. *J Invest Dermatol* 2010; 130: S22-S22.
- E320. Kim J, Son B, Lim D, Kim J, Kang H, Lee H. Effects of bio wallpaper on atopic dermatitis. *Allergy* 2011; 66: 124-124.
- E321. Kim M, Woo S. The efficacy and safety of pimecrolimus in children less than 2 year old: a randomised, controlled clinical trial. *Allergy* 2012; 67: 634-634.
- E322. Kircik L. Management of pruritus with levocetirizine dihydrochloride in atopic dermatitis in a randomised, double blind, placebo controlled study - Interim analysis. *Allergy Asthma Proc* 2010; 31: 166.
- E323. Kuznecovs I, Jegina K, Kuznecovs S. Atorvastatin and polyprenol effect on atopic dermatitis: pathogenesis links in adult patients. *Allergy* 2010; 65: 75-75.
- E324. Laumann A, Lai S, Lucky A, Schlessinger J, Jarratt M, Jones T, et al. The efficacy and safety of Mimyx Cream in reducing the risk of relapse in atopic dermatitis. *J Invest Dermatol* 2006; 126: 45-45.
- E325. Lebrun-Vignes B, Legrain V, Amoric J, Taieb A. [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis]. *Ann Dermatol Venereol* 2000; 127: 590-595.
- E326. Lee HJ, Park CO, Lee JH, Lee KH. The antipruritic effect of topical doxepin cream in patients with atopic dermatitis. *Korean Journal of Dermatology* 2006; 44: 309-314.
- E327. Lee KC, West D, Holbrook J, Kwasny M, Lio P. Novel use of a cooling pillow for treatment of severe head and neck atopic dermatitis. *J Am Acad Dermatol* 2013; 68: AB77-AB77.
- E328. Lembo C, Patruno C, de Leonibus C, Panariello L, Lembo S, Ayala F. [Topical erythromycin in atopic dermatitis.]. *Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale* 2011; 65: 113-118.
- E329. Levy A, Sheehan M, Roberts R. Tacrolimus cream 0.03% is safe and effective in the treatment of mild to moderate atopic dermatitis in adults. *J Allergy Clin Immunol* 2005; 115: S103.
- E330. Licu D, Pons-Guiraud A, Pigatto P, Lopez-Gil F, Ademola J, Balbul A, et al. Efficacy of thermal spring water in the treatment of mild atopic dermatitis. *Ann Dermatol Venereol* 2002; 129: 1S416.
- E331. Luna-Pech J, Newton-Sanchez O, Torres-Mendoza B, Garcia-Cobas C. Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to *Dermatophagoides pteronyssinus*. *Ann Allergy Asthma Immunol* 2013; 111: A8-A8.
- E332. Melamed I, Robinson L, Heffron M. The Benefit of Montelukast in Atopic Dermatitis Induced by Food Allergies. *J Allergy Clin Immunol* 2010; 125: AB93-AB93.
- E333. Misery L, Liège P, Cambazard F. Evaluation de l'efficacité et de la tolérance d'une crème contenant du raffinose au cours de la dermatite atopique. *Nouv Dermatol* 2005; 24: 339-341.
- E334. Mraz S, Miller B, Bucko A, Tschén E. A multicenter, double-blind, placebo-controlled study of the effectiveness of kiwi fruit extract in adults with atopic dermatitis of moderate severity. *J Am Acad Dermatol* 2006; 54: AB3-AB3.
- E335. Murosaki S, YAMAMOTO Y, YOTSUMOTO H, KUBO H, NOMOTO S, USUKI K, et al. Effects of intake of syrup supplemented with nigerooligosaccharides and heat-killed *Lactobacillus plantarum* L-137 on skin symptom and immune function in patients with atopic dermatitis. *Japanese Pharmacology and Therapy* 2006; 34: 1087.
- E336. Nakagawa H, Kawashima M. Efficacy and Safety of Fexofenadine Hydrochloride in Pediatric Patients with Atopic Dermatitis in a Phase III, Randomized, Double-blind, Multi-center Comparative Study. *Nishi Nihon Hifuka* 2006; 68: 553-565.
- E337. Namazova-Baranova L, Vishneva E, Levina J, Torshkoeva R, Alekseeva A, Efendieva K, et al. Combined therapy of atopic dermatitis in children. *Allergy* 2012; 67: 181-182.
- E338. Nieto A, For P. Efficacy and safety of pimecrolimus cream 1% in infants with mild-to-moderate atopic dermatitis: a randomised 5-year study. *Allergy* 2012; 67: 16-17.
- E339. Nunez C, Hogan D, Humphrey M, Zhang P, Lisante T, Doshi U. A colloidal oatmeal OTC cream is as clinically effective as a prescription barrier repair cream for the management of mild to moderate atopic dermatitis in African American children. *J Am Acad Dermatol* 2013; 68: AB73-AB73.
- E340. Oh S, Kwon S, Park H, Seo J, Choi H, Chung J. Antioxidant supplement had a lower effect of atopic dermatitis in young children: A randomized, double-blind, placebo-controlled, clinical trial. *Ann Nutr Metab* 2013; 63: 1358-1358.
- E341. Ozawa M, Numata I, Watabe A, Koizumi H, Memezawa A, Kikuchi K, et al. Effect of Underwear Made from MEDIELE® on Skin Barrier Function of Atopic Dermatitis Patients in Winter Season. *Hifu no kagaku* 2008; 7: 475-481.
- E342. Rikken G, Gertner J. SUN13834 in the Treatment of Subjects with Atopic Dermatitis. *J Invest Dermatol* 2010; 130: S69-S69.
- E343. Rossi AM, Ortonne JP, Guillet G, Dubertret L, Lahfa M, Griffiths C, et al. Efficacy and safety comparison of desonide 0.05% lotion versus fluocortolone 0.5% ointment in atopic dermatitis. *Ann Dermatol Venereol* 2002; 129: 1S420.
- E344. Rubio-Gomis E. Randomized controlled, double blind trial of topical twice weekly fluticasone propionate maintenance treatment to reduced risk of relapse in mild or moderate atopic dermatitis (AD) in children. *Basic Clin Pharmacol Toxicol* 2012; 111: 30.
- E345. Shi YJ, Zhang CM, Ma DM. [Clinical study on treatment of atopic dermatitis by integrated traditional Chinese and Western medicine]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2008; 28: 686-688.
- E346. Silny W, Czarnecka-Operacz M. [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study]. *Pol Merkur Lekarski* 2006; 21: 558-565.
- E347. Slavyanskaya T, Derkach V. Immunotherapy rationale in children with exacerbation of moderate atopic dermatitis. *Allergy* 2013; 68: 161-161.
- E348. Smith C, Ormerod A. Pimecrolimus cream 1% once-daily maintenance therapy for the prevention of relapse in mild to moderate atopic dermatitis in adults. *British Journal of Dermatology* 2005; 153: 37-37.
- E349. Span L. Intensieve DagBehandeling voor jonge volwassenen met atopisch eczeem. *Nederlands Tijdschrift voor Dermatologie*

- logie & Venereologie 2001; 11: 279-283.
- E350. Stein-Gold L. Safety and Efficacy of AN2728 Topical Ointment, 2% and 0.5%, in a Phase 2 Dose-Ranging Study of Adolescents with Mild-to-Moderate Atopic Dermatitis. *Pediatr Dermatol* 2013; 30: 646.
- E351. Sugai J. Combination therapy with 0.1% tacrolimus ointment and cetirizine for facial atopic dermatitis. *J Eur Acad Dermatol Venereol* 2003; 17: 174.
- E352. Thaci D. Treatment effects of 1% pimecrolimus ointment formulations in adult patients with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2005; 19: 218.
- E353. Thaci D, Worm M, Ren H, Weinstein S, Graham N, Pirozzi G, et al. Safety and Efficacy Of Dupilumab Versus Placebo For Moderate-To-Severe Atopic Dermatitis In Patients Using Topical Corticosteroids (TCS): Greater Efficacy Observed With Concomitant Therapy Compared To TCS Alone. *J Allergy Clin Immunol* 2014; 133: AB192-AB192.
- E354. Togawa Y, Kambe N, Shimojo N, Mochizuki H, Matsuda H, Tanaka A, et al. Ultrapure soft water improves the skin barrier function of child atopic dermatitis: the first report. *J Invest Dermatol* 2012; 132: S68-S68.
- E355. Wananukul S, Chatproedprai S, Chunharas A, Limpongsanuruk W, Singalavanija S, Chantorn R, et al. Comparison study of moisturiser containing licochalcone A and 1% hydrocortisone in the treatment of childhood atopic dermatitis. *Allergy* 2012; 67: 634-634.
- E356. Wang Y-w, Meng B-x. The efficacy of de-escalation therapy on the treatment of chronic eczema. *Journal of Clinical Dermatology* 2010; 40: 303-305.
- E357. Yang X-y. The adjuvant treatment of atopic dermatitis with medical skin preparation containing extracts from *Portulaca oleracea* and avocado. *Journal of Clinical Dermatology* 2010; 39: 460-462.
- E358. Yuen NS. Does order of application of emollient and topical corticosteroids make a difference to severity in children with atopic eczema? *European Journal of Pediatric Dermatology* 2012; 22: 14-15.
- E359. Zane L, Gogoleva T, Heerinx F, Jermano J. Safety and efficacy of AN2728 and AN2898 ointments in a phase 2a bilateral study of mild-to-moderate atopic dermatitis. *J Invest Dermatol* 2012; 132: S90-S90.
- E360. Cheon C, Park S, Park JS, Oh SM, Jang S, Go HY, et al. KM110329 in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, multicentre trial--study protocol. *BMC Complement Altern Med* 2013; 13: 335.
- E361. Eichenfield L. A randomized, double-blind, placebo-controlled, parallel group study of nanocrystalline silver (NPI 32101) cream in pediatric atopic dermatitis (AD). *J Am Acad Dermatol*; 56: AB75.
- E362. Hanifin J. A novel topical nuclear factor kappa-B decoy: Results from a phase I/II trial in atopic dermatitis. *J Am Acad Dermatol* 2006; 54: AB4.
- E363. Hanifin J, Hultsch T, Paller A, Eichenfield L. The demographic profile of a large population of infants with atopic dermatitis: A longitudinal study on development of asthma and allergies. *J Am Acad Dermatol* 2007; 56: AB68.
- E364. Kaur M, Feldman S, Clark A, Inabinet R. Adherence to topical hydrocortisone 17-butyrate 0.1% using different vehicles in adults with atopic dermatitis *J Am Acad Dermatol* 2007; 56: AB74.
- E365. Kim NK, Lee DH, Seo HS, Sun SH, Oh YL, Kim JE, et al. Hwangryunhaedoktang in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial--study protocol. *BMC Complement Altern Med* 2011; 11: 68.
- E366. Lara-Corrales I, Gomez G, de los Rios C, Pope E. Vitamin D in patients with atopic dermatitis: A randomized, double-blinded, placebo-controlled study preliminary analysis. *Pediatr Dermatol* 2013; 30: 638.
- E367. Tan HY, Zhang AL, Xue CC, Chen D, Da Costa C, Lenon GB. Evaluation of the efficacy and safety of a Chinese herbal formula (RCM-106) for atopic dermatitis: study protocol for a randomised, double-blind, placebo-controlled trial in children. *BMJ Open* 2013; 3: e003906.
- E368. Weston S, Richmond P, Halbert A, Prescott S. Effects of probiotics in infants with atopic dermatitis: a randomised double blind placebo controlled trial. *Australas J Dermatol* 2003; 44: A13.
- E369. Otsuki M, Nakagawa H, Kawashima M, Shibata Y, Harada S. Efficacy and safety of FK506 (tacrolimus) ointment in children with atopic dermatitis: phase III double-blinded comparison with vehicle ointment. *J Clin Ther Med (Japanese)* 2003; 19: 569-595.
- E370. Salavec M, Buckova H. First experiences with 1% Pimecrolimus cream therapy in prevention of atopic eczema flares in children. *Cesko-slovenska dermatologie* 2004; 79: 3-7.
- E371. Shibagaki N, Inozume T, Ando N, Kitamura R, Mizutani M, Nagasaka A, et al. Clinical Efficacy of Bath Additive Containing a Diamide Derivative in Patients with Atopic Dermatitis. *Nishi Nihon Hifuka* 2005; 67: 152-159.
- E372. Smitt JS, Spuls P, van Leent E, de Vries H, Mulder P, Glazenburg E, et al. Moet men kinderen met constitutioneel eczeem continu of in pulse lokaal behandelen met corticosteroiden? Een prospectieve gerandomiseerde dubbelblinde studie met clobetasol butyrate. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2000; 10: 204-205.
- E373. 中川秀己. 塩酸エピナスチンドライシロップの小児アトピー性皮膚炎に対する第 III 相臨床試験-フマル酸ケトフェンドライシロップを対照薬とした二重盲検群間比較試験-. *西日本皮膚科* 2004; 66.
- E374. Fukuie T, Nomura I, Narita M, Suzuki T, Tajima I, Natsume O, et al. A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Proactive Management in Pediatric Subjects with Moderate to Severe Atopic Dermatitis. *J Allergy Clin Immunol*; 131: AB101.
- E375. Hon KL, Leung TF, Ng PC, Lam MC, Kam WY, Wong KY, et al. Therapeutic effect and safety of a traditional Chinese medicine for atopic dermatitis in children: a randomised, double-blind, placebo-controlled study. *Hong Kong Med J* 2011; 17 Suppl 2: 38-40.
- E376. Kuznecova G, Kuznecovs I, Joksta I, Jegina K. Polyprenol with atorvastatin could improve management of atopic dermatitis. *Allergy* 2013; 68: 1.
- E377. Meggitt S, Gray J, Reynolds N. Parallel-group, randomized controlled trial of azathioprine in moderate to severe atopic eczema, using a thiopurine methyltransferase-based dose regimen. *Br J Dermatol* 2003; 149: 3.
- E378. Ramon G, Cambazard F. Evaluation of the corticosteroid-sparing effect of a new emollient in 162 atopic infants. *J Eur Acad Dermatol Venereol* 2006.